{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:41:46Z","timestamp":1792010506123,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejca.2025.115372","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T14:40:46Z","timestamp":1743950446000},"page":"115372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I\/II melanoma who did not undergo sentinel lymph node biopsy"],"prefix":"10.1016","volume":"220","author":[{"given":"Teresa","family":"Amaral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eftychia","family":"Chatziioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alica","family":"Nuebling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Nanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Sinnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Niessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Arentsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy","family":"Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jvalini","family":"Dwarkasing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Forchhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115372_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejso.2016.06.407","article-title":"Complications of sentinel lymph node biopsy for melanoma - a systematic review of the literature","volume":"43","author":"Moody","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archsurg.140.1.85","article-title":"Identifying risk factors for complications following sentinel lymph node biopsy for melanoma","volume":"140","author":"Roaten","year":"2005","journal-title":"Arch Surg"},{"key":"10.1016\/j.ejca.2025.115372_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115372_bib4","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1200\/JCO.2003.07.170","article-title":"Clinical outcome of stage I\/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results","volume":"21","author":"Vuylsteke","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.1999.17.3.976","article-title":"Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients","volume":"17","author":"Gershenwald","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib6","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1245\/s10434-019-07204-2","article-title":"Trends in sentinel lymph node biopsy enactment for cutaneous melanoma","volume":"26","author":"El Sharouni","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib8","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment \u2013 Update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115372_bib9","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1200\/JCO.23.01136","article-title":"Systemic Therapy for Melanoma: ASCO Guideline Update","volume":"41","author":"Seth","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib10","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1245\/s10434-016-5646-9","article-title":"Thin melanoma with nodal involvement: analysis of demographic, pathologic, and treatment factors with regard to prognosis","volume":"24","author":"Karakousis","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/XCS.0000000000001296","article-title":"Predictors of sentinel lymph node biopsy in thin melanoma: understanding the impact of the American joint commission on cancer 8th edition staging system","author":"Donica","year":"2025","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejca.2025.115372_bib12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/jso.26723","article-title":"More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: a Danish population-based study of 7148 patients","volume":"125","author":"Weitemeyer","year":"2022","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib13","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1245\/s10434-017-5842-2","article-title":"Quality of life following sentinel node biopsy for primary cutaneous melanoma: health economic implications","volume":"24","author":"Morton","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib14","doi-asserted-by":"crossref","DOI":"10.4021\/jcs33w","article-title":"Occurrence of lymphedema following sentinel node biopsy (SNB) for lower extremity melanoma","author":"Magoon","year":"2012","journal-title":"J Curr Surg"},{"key":"10.1016\/j.ejca.2025.115372_bib15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","article-title":"Stage-specific risk of recurrence and death from melanoma in Denmark, 2008-2021: a national observational cohort study of 25 720 patients with stage IA to IV melanoma","volume":"159","author":"Helvind","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2025.115372_bib16","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas (\u2a7d1 mm) than from thick melanomas (>4 mm) in Queensland, Australia","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2025.115372_bib17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2016.10.018","article-title":"Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013","volume":"76","author":"Landow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2025.115372_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113989","article-title":"Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy","volume":"202","author":"K\u00f6tt","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115372_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejca.2022.12.022","article-title":"Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma","volume":"182","author":"van Akkooi","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115372_bib20","article-title":"Adjuvant systemic therapy in melanoma: relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?","volume":"2","author":"van Akkooi","year":"2024","journal-title":"EJC Ski Cancer"},{"key":"10.1016\/j.ejca.2025.115372_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2022.12.021","article-title":"Identification of stage I\/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP)","volume":"182","author":"Amaral","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115372_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/PO.19.00206","article-title":"Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma","volume":"4","author":"Bellomo","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2024.10.124","article-title":"Acral lentiginous melanoma. Part I. epidemiology, etiology, clinical presentation, and diagnosis","author":"Thakker","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"32","key":"10.1016\/j.ejca.2025.115372_bib24","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.22.00202","article-title":"Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment","volume":"40","author":"Garbe","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2217\/fon-2018-0912","article-title":"Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling","volume":"15","author":"Vetto","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib26","doi-asserted-by":"crossref","first-page":"9066","DOI":"10.1200\/jco.2015.33.15_suppl.9066","article-title":"Continued evaluation of a 31-gene expression profile test (GEP) for prediction of distant metastasis (DM) in cutaneous melanoma (CM)","volume":"33","author":"Lawson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115372_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"ky032","key":"10.1016\/j.ejca.2025.115372_bib28","article-title":"A prognostic gene signature expressed in primary cutaneous melanoma: synergism with conventional staging","volume":"2","author":"Brunner","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ejca.2025.115372_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2020.10.016","article-title":"Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients","volume":"143","author":"Gambichler","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115372_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2020.08.029","article-title":"Identification of stage I\/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model","volume":"140","author":"Eggermont","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115372_bib31","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/cancers14122854","article-title":"Using a clinicopathologic and gene expression (CP-GEP) model to identify stage I-II melanoma patients at risk of disease relapse","volume":"14","author":"Mulder","year":"2022","journal-title":"Cancers"},{"issue":"nr. 7602","key":"10.1016\/j.ejca.2025.115372_bib32","article-title":"Impact of CP-GEP to improve selection of patients with melanoma who may forgo sentinel lymph node biopsy based on real world data","author":"Stassen","year":"2024","journal-title":"Abstr Book EADV Congr"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:49:57Z","timestamp":1760640597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925001534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"alternative-id":["S0959804925001534"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115372","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I\/II melanoma who did not undergo sentinel lymph node biopsy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115372"}}